Social Media Ideas for Nbix

Neurocrine Biosciences: 'House Full Of Options'

NexTel Medical Corp. Executes Letter of Intent to Acquire 100% of Xycota Biosciences, LLC

Strategic Acquisition Positions NexTel at the Forefront of Precision Neuro-Restoration with Xycota's Breakthrough Exosome-Delivered Brain Circuitry Repair Platform and Pending FDA...

BioXcel

BioXcel Anonymous (not verified) Sun, 08/30/2026 - 09:43 field_thread_url https://cafepharma.com/boards/threads/bioxcel.674502/ board na...

Inhibrx Biosciences: The Whole Story Rides On INBRX-106

BioXcel files for Chapter 11, will sell assets to Teva

INmune Bio (INMB) Q2 2026 Earnings Call Transcript

Ebstracel nears UK filing as XPro shows Alzheimer's biomarker progress.

Nebius (NBIS) Q2 2026 Earnings Call Transcript

AI cloud revenue surged 514% year-over-year as customer prepayments hit $9 billion.

AtaiBeckley: 'Hold'; Eli Lilly Acquisition For $2.8 Billion Adds To Its Neuroscience Pipeline

<![CDATA[Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia]]>

TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors

Nebius: Why Its Post-Earnings Momentum Has Staying Power

Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing

Acquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome (CRPS)Up to $77 million in pr...

StockWatch: Lilly’s Up-to-$3.8B Deal for AtaiBeckley a Good Trip for Psychedelic Drugs, Analysts and Investors Agree

Eli Lilly agreed to acquire AtaiBeckley for up to $3.8 billion—of which Lilly will pay $2.8 billion upfront. The deal, set to close in the third quarter, expands Lilly’s neuroscien...

ImmunityBio: ANKTIVA's Commercial Momentum Supports A Buy

New drug data could lift shares of this biotechnology stock, Truist says

Biogen could see more upside if it publishes positive results from recent trials linked to kidney and Alzheimer's treatments, Truist Securities says. 

Brookmount Explorations Inc. (BMXI) Completes Acquisition of Mentor AI Corp

All-stock acquisition marks the Company's entry into artificial-intelligence technologies

Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?

Nexity SA 2026 Q2 - Results - Earnings Call Presentation

Belhaven Announces Significant Expansion of Nasdepi Patent Portfolio, Commercial Supply Readiness, and FDA Alignment on...

Pivotal Clinical Study Poised to Start in Q3 2026

Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat

Investors awaiting Bristol Myers Squibb’s key Alzheimer’s psychosis readout for Cobenfy and atrial fibrillation data for milvexian will have to wait a little longer.

Pyxis Oncology: The Market Might Have Already Ruled On Micvotabart Pelidotin

A Deeper Dive Into Design Therapeutics

Nvidia Delivers Fantastic News for Nebius Stock Investors!

The capital infusion will go a long way for Nebius.

Sibannac, Inc. (OTCID:SNNC) Enters Into Non-Binding Letter of Intent for Strategic Collaboration and Potential Reverse M...

Special Purpose Vehicle to Be Formed in Connection With Proposed Transaction